SCHEMBL14999529

SCHEMBL14999529

C=Cc1cccc(C(C)(C)c2ccccc2)c1OC

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.36
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
ALDH1A1 P00352 5/20 0.33
ESR1 P03372 1/20 0.33
CYP3A4 P08684 1/20 0.33
ESR2 Q92731 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MAPK1 P28482 2/20 0.32
ALOX15 P16050 1/20 0.31
TNFRSF1A P19438 1/20 0.31
KDM4E B2RXH2 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
TRPA1 O75762 1/20 0.30
TRPM8 Q7Z2W7 1/20 0.30
DRD2 P14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16253603 0.84 NFE2L2 (0.34) NFE2L2PDE4APDE4BPDE4CPDE4D
SCHEMBL19124043 0.83 NFE2L2 (0.42) NFE2L2PDE4APDE4BPDE4CPDE4D
SCHEMBL15427432 0.83 NFE2L2 (0.42) NFE2L2PDE4APDE4BPDE4CPDE4D
SCHEMBL15002486 0.82 ALOX12 (0.39) NFE2L2ALDH1A1CA1CA2TNFRSF1A
SCHEMBL4789180 0.81 ALDH1A1 (0.41) ALDH1A1ESR1CYP3A4ESR2MAPK1
SCHEMBL18762626 0.81 RARG (0.34) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL14999528 0.80 CA1 (0.36) NFE2L2ALDH1A1CA1CA2MAPK1
SCHEMBL16134874 0.77 PTGS2 (0.35) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL16951902 0.75 CA1 (0.45) NFE2L2ALDH1A1CA1CA2MAPK1
SCHEMBL15002480 0.74 CA1 (0.34) NFE2L2CA1CA2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2966108-B1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS SAUDI ARAMCO TECH CO (SA) 2021-03-31 EP disclosed
US-20170183369-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2017-06-29 US disclosed
US-9505878-B2 Catalysts and methods for polymer synthesis NOVOMER, INC. (US) 2016-11-29 US disclosed
US-9403861-B2 Salen complexes with dianionic counterions NOVOMER, INC. (US) 2016-08-02 US disclosed
US-20150252145-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2015-09-10 US disclosed
US-8951930-B2 Catalysts and methods for polymer synthesis NOVOMER, INC. (US) 2015-02-10 US disclosed
US-8946109-B2 Catalysts and methods for polymer synthesis NOVOMER, INC. (US) 2015-02-03 US disclosed
US-20140336354-A1 SALEN COMPLEXES WITH DIANIONIC COUNTERIONS SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2014-11-13 US disclosed
US-20130144032-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS NOVOMER, INC. (US) 2013-06-06 US disclosed
US-20130144031-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS NOVOMER, INC. (US) 2013-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336354-A1 SALEN COMPLEXES WITH DIANIONIC COUNTERIONS NCLN, POLN, NCL NFE2L2 4010/4885PDE4A 3301/4885PDE4B 3352/4885
US-20130144032-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS PPOX, COASY, SOD1 NFE2L2 521/4885PDE4A 4210/4885PDE4B 4456/4885
US-20170183369-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS PPOX, COASY, SOD1 NFE2L2 521/4885PDE4A 4210/4885PDE4B 4456/4885
US-20150252145-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS PPOX, COASY, SOD1 NFE2L2 521/4885PDE4A 4210/4885PDE4B 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.